title: Definition of the mitogenic factor (MF) as a novel streptococcal superantigen that is different from streptococcal pyrogenic exotoxins A, B, and C.
abstract: Human T cell activation by recombinant mitogenic factor (rMF) was investigated in comparison with that by recombinant streptococcal pyrogenic exotoxins (rSPE) A, B, and C. Recombinant MF, rSPEA, and rSPEC were mitogenic for peripheral blood mononuclear cells (PBMC), whereas rSPEB was not. Recombinant MF required only HLA-DR for the stimulation of PBMC, as determined using monoclonal antibodies (mAb) to HLA class II molecules and the mouse L cells transfected with HLA class II molecules. Recombinant SPEA and rSPEC required HLA-DR or HLA-DQ molecule. Recombinant MF selectively stimulated V beta 2, V beta 7, V beta 8, V beta 18 and V beta 21-bearing T cells, whereas rSPEA and rSPEC activated V beta 2 and V beta 6-bearing T cells as evaluated by the quantitative T cell receptor (TCR) analytical method. No clonality was observed in the nucleotide sequences of complementarity determining region 3 of TCR V beta in T cells responding to rMF. The profiles of cytokine production by PBMC in response to rMF, rSPEA, and rSPEC were quite similar. In summary, these results demonstrate that both HLA class II molecules and the TCR V beta required for rMF-mediated T cell activation are distinct from those required for rSPEA or rSPEC-mediated activation. Therefore, the MF is a novel streptococcal super-antigen which is different from SPEA, SPEB, and SPEC.
authors.affiliation: Research Unit, Shionogi & Co., Ltd., Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Toyosaki
authors.forename: T
authors.initials: T
authors.lastname: Yoshioka
authors.forename: Y
authors.initials: Y
authors.lastname: Tsuruta
authors.forename: T
authors.initials: T
authors.lastname: Yutsudo
authors.forename: M
authors.initials: M
authors.lastname: Iwasaki
authors.forename: R
authors.initials: R
authors.lastname: Suzuki
mesh_terms: D001426:Bacterial Proteins / Q000737:chemistry* / Q000235:genetics / Q000494:pharmacology; D005098:Exotoxins / Q000737:chemistry* / Q000276:immunology / Q000494:pharmacology; D006684:HLA-DR Antigens / Q000096:biosynthesis; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008565:Membrane Proteins; D008934:Mitogens / Q000737:chemistry* / Q000235:genetics / Q000494:pharmacology; D011749:Pyrogens / Q000737:chemistry* / Q000276:immunology / Q000494:pharmacology; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000096:biosynthesis / Q000235:genetics; D013297:Streptococcus pyogenes / Q000276:immunology*; D018089:Superantigens / Q000737:chemistry* / Q000494:pharmacology
chemical_list: D001426:Bacterial Proteins; D005098:Exotoxins; D006684:HLA-DR Antigens; D008565:Membrane Proteins; D008934:Mitogens; D011749:Pyrogens; D016693:Receptors, Antigen, T-Cell, alpha-beta; C117980:SpeA protein, Streptococcus pyogenes; D018089:Superantigens; C027951:erythrogenic toxin; C083356:mitogenic factor, Streptococcus